DK422475A - - Google Patents

Info

Publication number
DK422475A
DK422475A DK422475A DK422475A DK422475A DK 422475 A DK422475 A DK 422475A DK 422475 A DK422475 A DK 422475A DK 422475 A DK422475 A DK 422475A DK 422475 A DK422475 A DK 422475A
Authority
DK
Denmark
Application number
DK422475A
Other languages
Danish (da)
Other versions
DK141773B (en
DK141773C (en
Inventor
D A L Davies
Original Assignee
Searle & Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co Ltd filed Critical Searle & Co Ltd
Publication of DK422475A publication Critical patent/DK422475A/da
Publication of DK141773B publication Critical patent/DK141773B/en
Application granted granted Critical
Publication of DK141773C publication Critical patent/DK141773C/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
DK422475AA 1974-09-20 1975-09-19 Process for preparing an anti-tumor agent. DK141773B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB4103774 1974-09-20
GB41037/74A GB1509707A (en) 1974-09-20 1974-09-20 Immunological compounds

Publications (3)

Publication Number Publication Date
DK422475A true DK422475A (en) 1976-03-21
DK141773B DK141773B (en) 1980-06-16
DK141773C DK141773C (en) 1980-11-03

Family

ID=10417824

Family Applications (1)

Application Number Title Priority Date Filing Date
DK422475AA DK141773B (en) 1974-09-20 1975-09-19 Process for preparing an anti-tumor agent.

Country Status (7)

Country Link
JP (1) JPS5161640A (en)
DE (1) DE2541931A1 (en)
DK (1) DK141773B (en)
FR (1) FR2285145A1 (en)
GB (1) GB1509707A (en)
NL (1) NL7511089A (en)
SE (1) SE7510505L (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067971A (en) * 1976-05-13 1978-01-10 The Procter & Gamble Company Therapeutic composition
JPS54132503A (en) * 1978-04-07 1979-10-15 Kayaku Antibiotic Research Co Immune globulin combined neocarcinostatin
JPS5665828A (en) * 1979-11-02 1981-06-03 Kureha Chem Ind Co Ltd Antitumor agent
US4315851A (en) 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
JPS5592325A (en) * 1978-12-29 1980-07-12 Kureha Chem Ind Co Ltd Antitumor agent and its preparation
JPS5665829A (en) * 1979-11-02 1981-06-03 Kureha Chem Ind Co Ltd Antitumor agent
EP0037388B1 (en) * 1980-03-31 1984-12-12 Institut International De Pathologie Cellulaire Et Moleculaire Pharmaceutical forms, their preparation and compositions containing the same
JPS58118520A (en) * 1982-01-09 1983-07-14 Hidematsu Hirai Antitumor proteinic complex and preparation thereof
JPS59186924A (en) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd Antitumor agent bonded with human immunoglobulin
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
DE3513572A1 (en) * 1985-04-16 1986-10-16 Karl Prof. Dr.med. 7302 Ostfildern Theurer Preparation of products for specifically influencing the humoral and cellular immune response
JPS62228025A (en) * 1985-12-27 1987-10-06 Teijin Ltd Production of antibody complex
WO1988007553A1 (en) * 1987-03-26 1988-10-06 Teijin Limited Process for preparing antibody complex
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof
DE4122210C2 (en) * 1991-07-04 1999-04-01 Deutsches Krebsforsch Tumor-active compound-serum albumin conjugates, process for their preparation and their use

Also Published As

Publication number Publication date
SE7510505L (en) 1976-03-22
DK141773B (en) 1980-06-16
JPS5161640A (en) 1976-05-28
GB1509707A (en) 1978-05-04
FR2285145B1 (en) 1980-05-30
DE2541931A1 (en) 1976-04-01
FR2285145A1 (en) 1976-04-16
NL7511089A (en) 1976-03-23
DK141773C (en) 1980-11-03

Similar Documents

Publication Publication Date Title
AU495844B2 (en)
JPS50124059A (en)
JPS50131942U (en)
AU7474374A (en)
AU480170A (en)
BG19607A1 (en)
BG20018A1 (en)
BG20186A1 (en)
BG20662A1 (en)
BG20665A1 (en)
BG20670A1 (en)
BG20724A1 (en)
BG20849A1 (en)
BG21661A1 (en)
BG21791A1 (en)
BG22011A1 (en)
BG22387A3 (en)
BG22667A1 (en)
BG26192A3 (en)
BG26358A3 (en)
BG26402A3 (en)
BG27047A4 (en)
BG27089A3 (en)
CH1637174A4 (en)
CH352875A4 (en)